To discuss the safety and effectiveness of the hysteroscopic tissue removal system (MyoSure) for treating intrauterine benign occupying lesions of patients. Methods: A retrospective analysis was carried out on the clinical data of 152 patients with intrauterine benign occupying lesions who had accepted MyoSure treatment from August, 2013 to March, 2023, including 108 patients with submucous uterine myomas, 29 with endometrial polyps and 15 with intrauterine pregnancy residues. The intra -operative indexes, the postoperative satisfaction with the curative effect and the follow-up situation of these patients were analyzed. The uterine fibroid symptoms-health-related quality of life questionnaire (UFS-QOL) was used to evaluate the symptom severity score (SSS) and health related quality of life (HRQL) score of the patients. Results: There were 152 patients with successful operation and without any serious complication. The average operation time, the average bleeding volume, the average uterine distention medium dosage and the satisfaction of the curative effect of the patients were 4.71±4.60 min, 9.11±18.89 ml, 602.63±186.62 ml and 94.7%, respectively. The scores of SSS and HRQL of the patients in 3 months after the operation (14.78±4.3 points and 78.82±6.31 points) and in 6 months after the operation (14.27±3.9 points and 80.37±5.48 points) were significantly higher than those (30.26±5.7 points and 65.73±5.26 points) before the operation (all P<0.01). The rates of the postoperative pregnancy and the recurrence of the patients were 57.8% and 2.6%. Conclusion: MyoSure for treating the intrauterine benign occupying lesions of the patients is safety and effectiveness, and with ideal curative outcomes.